There were 354 press releases posted in the last 24 hours and 153,678 in the last 365 days.

WindMIL Therapeutics Announces Promotions to Newly Created Leadership Roles as Part of Continued Growth

BALTIMORE, April 17, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the promotions of Kimberly Noonan, PhD, MPH, to Executive Vice President and Chief Scientific Officer and Patrick Dougherty to Vice President, Planning and Operations. Noonan previously served as Chief Scientific Officer and Dougherty as Vice President, Operations.

Patrick Dougherty
Patrick Dougherty


Kimberly Noonan, PhD, MPH
Kimberly Noonan, PhD, MPH


/EIN News/ -- “WindMIL congratulates Kim and Patrick on their well-deserved promotions,” said Don Hayden, Interim CEO and Executive Chairman of WindMIL Therapeutics. “Kim’s new position as Executive Vice President and Chief Scientific Officer recognizes the essential role she has played in WindMIL’s growth and maturation as both a co-founder and leader. Her vision for bringing MILs to patients will continue to drive us forward as we implement WindMIL’s strategic plan.”

“We’re also delighted to acknowledge Patrick for his dedication to assuming greater planning responsibilities since joining WindMIL in July 2018. As Vice President, Planning and Operations, Patrick will establish and lead strategic planning processes, drive associated business planning and work with the leadership team to set short- and long-term performance goals,” continued Hayden.

Dr. Noonan is a scientific cofounder of WindMIL along with Ivan Borrello, MD. Together, Drs. Borrello and Noonan pioneered the use of MILs for treating cancer. Dr. Noonan received her BS in Microbiology and PhD in Immunology from the University of Pittsburgh. She also holds an MPH from Johns Hopkins University. Dr. Noonan has published many peer-reviewed papers, review articles and book chapters, and holds several patents. She joined the faculty of Johns Hopkins University in 2004 and maintains an adjunct faculty appointment. 

Prior to joining WindMIL, Mr. Dougherty was Chief of Staff to the SVP R&D Pipeline for Pharmaceuticals R&D at GlaxoSmithKline (GSK). Mr. Dougherty joined GSK in 2009 as a Director in the R&D Strategy Office and went on to hold a number of leadership roles in R&D Strategy & Portfolio and Worldwide Business Development and to steer multiple strategic efforts for Pharmaceuticals R&D. He holds a BS in Chemistry from Villanova University, an MSc in Technology Management from the University of Manchester (UK) and an MBA from the Wharton School, University of Pennsylvania.

About WindMIL Therapeutics
WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow infiltrating lymphocytes (MILs™) for cancer immunotherapy. As the leader in cellular therapeutics emanating from bone marrow, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients. The company’s proprietary process to extract, activate and expand these cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxicity, and long persistence. For more information, please visit: https://windmiltherapeutics.com.

Media Contact:
Tony Plohoros
6 Degrees
(908) 940-0135
tplohoros@6degreespr.com  

Photos accompanying this announcement are available at:
 
http://www.globenewswire.com/NewsRoom/AttachmentNg/35795402-4797-4ef4-9a06-e80e329a973c

http://www.globenewswire.com/NewsRoom/AttachmentNg/9aa17105-a353-4eb2-bf97-c6f8cfdc21da

Full Color CMYK.jpg

Distribution channels:


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.